Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0278883 (
metastatic melanoma
)
6,224
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Insulin-like growth factor-II messenger RNA (mRNA)-binding protein-3 (
IMP-3
), also known as K homology domain-containing protein overexpressed in cancer (KOC) and L523S, is a member of the insulin-like growth factor-II mRNA-binding protein family and is expressed during embryogenesis and in some malignancies.
IMP-3
expression in melanocytic neoplasms has not been investigated. Fifty-six melanocytic neoplasms from 48 subjects were immunohistochemically studied using a monoclonal antibody against L523S/
IMP-3
.
IMP-3
expression in melanoma was significantly higher than in Spitz nevi (P<0.05), and the staining intensity in the Spitz nevi was weak.
IMP-3
expression in
metastatic melanoma
was significantly higher than in primary cutaneous melanoma with a Breslow depth </=1 mm (P<0.01). None of the benign nevi and dysplastic nevi expressed
IMP-3
. Our study demonstrates that
IMP-3
is expressed in malignant melanoma but not in benign nevi, even when dysplastic features are present;
IMP-3
is expressed in a significantly higher proportion of melanomas than Spitz nevi; and
IMP-3
is expressed in metastatic melanomas significantly more than in thin melanomas. In conclusion,
IMP-3
appears to be involved in the progression of malignant melanoma and may play an important role in the regulation of the biologic behavior of this tumor. Additionally,
IMP-3
may have diagnostic utility in distinguishing melanoma from benign nevic cells, dysplastic nevi, and Spitz nevi.
...
PMID:IMP-3 is a novel progression marker in malignant melanoma. 1820 32